{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:18:52Z","timestamp":1783117132462,"version":"3.54.6"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA072720"],"award-info":[{"award-number":["P30CA072720"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ucl.2026.03.011","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:17:26Z","timestamp":1777288646000},"page":"475-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-Centered Approaches to Non\u2013Muscle-Invasive Bladder Cancer Care"],"prefix":"10.1016","volume":"53","author":[{"given":"Melinda Z.","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pfail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ucl.2026.03.011_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus calmette-gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.011_bib3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews","volume":"12","author":"Lee","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.011_bib4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.011_bib5","doi-asserted-by":"crossref","first-page":"e0274859","DOI":"10.1371\/journal.pone.0274859","article-title":"Number of transurethral procedures after non-muscle-invasive bladder cancer and survival in causes other than bladder cancer","volume":"17","author":"Holmberg","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.011_bib6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.juro.2014.04.103","article-title":"Anticoagulation and antiplatelet therapy in urological practice: ICUD\/AUA review paper","volume":"192","author":"Culkin","year":"2014","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12894-025-01751-5","article-title":"The incidence and risk factors of urinary tract infections in patients undergoing bladder tumor resection: a systematic review and meta-analysis","volume":"25","author":"Lin","year":"2025","journal-title":"BMC Urol"},{"issue":"Suppl 3","key":"10.1016\/j.ucl.2026.03.011_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/JAD-2010-100807","article-title":"Long-term post-operative cognitive decline in the elderly: the effects of anesthesia type, apolipoprotein E genotype, and clinical antecedents","volume":"22","author":"Ancelin","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.011_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/21681805.2020.1782978","article-title":"Do repeated transurethral procedures under general anesthesia influence mortality in patients with non-invasive urothelial bladder cancer? A Danish national cohort study","volume":"54","author":"Erikson","year":"2020","journal-title":"Scand J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.011_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.011_bib11","doi-asserted-by":"crossref","first-page":"711.e1","DOI":"10.1016\/j.clgc.2023.04.011","article-title":"The impact of blue light cystoscopy use among nonmuscle invasive bladder cancer patients in an equal access setting: implications on recurrence and time to recurrence","volume":"21","author":"Das","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.011_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/CU9.0000000000000142","article-title":"The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer","volume":"16","author":"Cahill","year":"2022","journal-title":"Curr Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.011_bib13","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.juro.2017.11.096","article-title":"Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase III, comparative, multicenter study","volume":"199","author":"Daneshmand","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.euo.2020.06.010","article-title":"Best practices to optimise quality and outcomes of transurethral resection of bladder tumours","volume":"4","author":"Mostafid","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.011_bib15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1308\/rcsann.2016.0246","article-title":"Prediction of histological stage based on cystoscopic appearances of newly diagnosed bladder tumours","volume":"98","author":"During","year":"2016","journal-title":"Ann R Coll Surg Engl"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.011_bib16","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0022-5347(05)64555-7","article-title":"Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder","volume":"168","author":"Herr","year":"2002","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.011_bib17","first-page":"8198","article-title":"Short term complications from transurethral resection of bladder tumor","volume":"23","author":"Gregg","year":"2016","journal-title":"Can J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.011_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000056589","article-title":"The pathophysiology, diagnosis and therapy of the transurethral resection of the prostate syndrome","volume":"66","author":"Balzarro","year":"2001","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.011_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.29271\/jcpsp.2024.02.230","article-title":"Comparison of monopolar versus bipolar repeat transurethral resection of bladder tumours","volume":"34","author":"Cetin","year":"2024","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.ucl.2026.03.011_bib20","series-title":"Management of non-muscle invasive bladder cancer","first-page":"365","article-title":"Bladder cancer survivorship and patient reported outcome measures\u2014code 5 impact of operation on general health","author":"Goonewardene","year":"2020"},{"key":"10.1016\/j.ucl.2026.03.011_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/5584_2018_264","article-title":"Influence of transurethral resection of bladder cancer on sexual function, anxiety, and depression","volume":"1116","author":"Krajewski","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.011_bib22","doi-asserted-by":"crossref","first-page":"117.e1-e10","DOI":"10.1016\/j.urolonc.2023.12.007","article-title":"Symptomatic and functional recovery after transurethral resection of bladder tumor: data from ecological momentary symptom assessment","volume":"42","author":"Strother","year":"2024","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12871-018-0659-5","article-title":"Tramadol for the treatment of catheter-related bladder discomfort: a randomized controlled trial","volume":"18","author":"Li","year":"2018","journal-title":"BMC Anesthesiol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.011_bib24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/bja\/ael048","article-title":"Ketamine for treatment of catheter related bladder discomfort: a prospective, randomized, placebo controlled and double blind study","volume":"96","author":"Agarwal","year":"2006","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.011_bib25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/iju.15100","article-title":"Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter related bladder discomfort in transurethral resection of bladder tumors: a randomized, double blind, controlled trial","volume":"30","author":"Singh","year":"2023","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1213\/ANE.0000000000004405","article-title":"Intravenous lidocaine for the prevention of postoperative catheter-related bladder discomfort in Male patients undergoing transurethral resection of bladder tumors: a randomized, double-blind, controlled trial","volume":"131","author":"Kim","year":"2020","journal-title":"Anesth Analg"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.011_bib27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00228-021-03251-5","article-title":"Different interventions for preventing postoperative catheter-related bladder discomfort: a systematic review and meta-analysis","volume":"78","author":"Li","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.011_bib28","doi-asserted-by":"crossref","first-page":"70.e1-e10","DOI":"10.1016\/j.urolonc.2024.01.013","article-title":"Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: insights from qualitative interviews and a cross-sectional survey","volume":"42","author":"Kopenhafer","year":"2024","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.011_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.101811","article-title":"Selecting the right treatment: health outcome priorities in older patients with bladder cancer","volume":"15","author":"Rutten","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.011_bib30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1200\/JCO-25-01324","article-title":"Twelve-month results from the CISTO study comparing radical cystectomy versus bladder-sparing therapy for recurrent high-grade non-muscle-invasive bladder cancer","volume":"44","author":"Gore","year":"2026","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.011_bib31","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1080\/03007995.2024.2411424","article-title":"Overall burden and impact on health-related quality of life associated with intravesical treatment of patients with non-muscle invasive bladder cancer in the United States","volume":"40","author":"Totev","year":"2024","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.011_bib32","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.011_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.euros.2023.08.004","article-title":"Quality of life in patients with high-grade non-muscle-invasive bladder cancer undergoing standard versus reduced frequency of bacillus calmette-gu\u00e9rin instillations: the EAU-RF NIMBUS trial","volume":"56","author":"van Straten","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.011_bib35","first-page":"6145","article-title":"Association between urine 6-sulfatoxy-melatonin level and intravesical bacillus calmette-guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer","volume":"30","author":"Miyake","year":"2022","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib36","first-page":"887","article-title":"Intravesical bacillus calmette-guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy","volume":"30","author":"Miyake","year":"2022","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.011_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.02.010","volume":"22","author":"Montgomery","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"10.1016\/j.ucl.2026.03.011_bib38","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/brainsci14121203","article-title":"Peripheral mechanisms underlying bacillus calmette-guerin-induced lower urinary tract symptoms (LUTS)","volume":"14","author":"Elmasri","year":"2024","journal-title":"Brain Sci"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.011_bib39","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1159\/000524098","article-title":"Quality of life, efficacy, and safety of sequential intravesical gemcitabine + docetaxel versus BCG for non-muscle invasive urinary bladder cancer: a pilot study","volume":"106","author":"Pareek","year":"2022","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.011_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000004296","article-title":"Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION)","volume":"213","author":"Prasad","year":"2025","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.011_bib41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/JU.0000000000002747","article-title":"Minimal patient-reported side effects for a chemoablative Gel (UGN-102) used as frontline treatment in adults with nonmuscle-invasive bladder cancer","volume":"208","author":"Stover","year":"2022","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.eururo.2025.02.010","article-title":"A systematic review of novel intravesical approaches for the treatment of patients with non-muscle-invasive bladder cancer","volume":"88","author":"Ghodoussipour","year":"2025","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.011_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus calmette-gu\u00e9rin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.011_bib44","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/UPJ.0000000000000517","article-title":"Quality of life in the phase 2\/3 trial of N-803 plus bacillus calmette-gu\u00e9rin in bacillus calmette-gu\u00e9rin\u2012unresponsive nonmuscle-invasive bladder cancer","volume":"11","author":"Chamie","year":"2024","journal-title":"Urol Pract"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.011_bib45","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.011_bib46","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus calmette-guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.011_bib47","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2010.11.038","volume":"59","author":"Oosterlinck","year":"2011","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.011_bib48","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s13193-021-01439-w","article-title":"Intravesical bacillus calmette-guerin (BCG) therapy for non-muscle invasive bladder cancers: long-term results of a modified schedule","volume":"12","author":"Malik","year":"2021","journal-title":"Indian J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12301-020-00099-6","article-title":"Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience","volume":"26","author":"Sharma","year":"2020","journal-title":"Afr J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.011_bib50","first-page":"167","article-title":"A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy","volume":"80","author":"Mangiarotti","year":"2008","journal-title":"Arch Ital Urol Androl"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000471653","article-title":"Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Gu\u00e9rin) in superficial bladder cancer","volume":"20","author":"Rintala","year":"1991","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib52","first-page":"Cd011935","article-title":"Intravesical bacillus calmette-gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.011_bib53","doi-asserted-by":"crossref","first-page":"e230849","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus calmette-gu\u00e9rin for the treatment of patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.011_bib54","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.011_bib55","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.011_bib56","doi-asserted-by":"crossref","first-page":"458.e1","DOI":"10.1016\/j.urolonc.2023.06.018","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib58","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with bacillus calmette-gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib59","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"issue":"33","key":"10.1016\/j.ucl.2026.03.011_bib60","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO-25-01651","article-title":"TAR-200 for bacillus calmette-gu\u00e9rin\u2013unresponsive high-risk non\u2013muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.011_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjon.2022.04.002","article-title":"Quality of life patterns and its association with predictors among non-muscle invasive bladder cancer survivors: a latent profile analysis","volume":"9","author":"Park","year":"2022","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.011_bib62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.euo.2024.08.001","article-title":"Deintensification of treatment for low-grade bladder tumors: a collaborative review by the international bladder cancer group (IBCG)","volume":"8","author":"Contieri","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.011_bib63","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.011_bib64","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3233\/BLC-201535","article-title":"A randomized feasibility trial comparing surveillance regimens for patients with low and low-intermediate risk non-muscle invasive bladder cancer","volume":"7","author":"Reyes","year":"2021","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.011_bib65","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/JU.0000000000001515","article-title":"Cost-effectiveness analysis of pembrolizumab for bacillus calmette-gu\u00e9rin-unresponsive carcinoma in situ of the bladder","volume":"205","author":"Wymer","year":"2021","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.011_bib66","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.21873\/anticanres.16540","article-title":"Factors related to overactive bladder-like symptoms in bladder cancer","volume":"43","author":"Tachibana","year":"2023","journal-title":"Anticancer Res"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.011_bib67","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3390\/cancers16101936","article-title":"Use of bladder-related medication in non-muscle invasive bladder cancer patients","volume":"16","author":"Blichert-Refsgaard","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.011_bib68","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MOU.0000000000000894","article-title":"Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2","volume":"31","author":"Zimmermann","year":"2021","journal-title":"Curr Opin Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.011_bib69","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.21037\/tau-20-1333","article-title":"Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer-a systematic review","volume":"10","author":"Nayak","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.011_bib70","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.euo.2023.11.007","article-title":"Health-related quality of life during the first 4 years after non-muscle-invasive bladder cancer diagnosis: results of a large multicentre prospective cohort","volume":"7","author":"Beeren","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.011_bib71","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.011_bib72","first-page":"6175","article-title":"Relationships among uncertainty, post-traumatic stress disorder symptoms, and quality of life in non-muscle-invasive bladder cancer survivors","volume":"30","author":"Jung","year":"2022","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.011_bib73","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0277-9536(91)90150-B","article-title":"The MOS social support survey","volume":"32","author":"Sherbourne","year":"1991","journal-title":"Soc Sci Med"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.011_bib74","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036871","article-title":"Effectiveness of integrated nursing interventions in enhancing patient outcomes during postoperative intravesical instillation for non-muscle invasive bladder cancer: a comparative study","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine (Baltim)"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.011_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-076763","article-title":"ERAS for ambulatory TURBT: enhancing bladder cancer care (EMBRACE) randomised controlled trial protocol","volume":"14","author":"Rezaee","year":"2024","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.011_bib76","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/ijc.34418","article-title":"Longitudinal associations of adherence to lifestyle recommendations and health-related quality of life in patients with non-muscle invasive bladder cancer","volume":"152","author":"Vidra","year":"2023","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.011_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055782","article-title":"Bladder cancer and exeRcise trAining during intraVesical thErapy-the BRAVE trial: a study protocol for a prospective, single-centre, phase II randomised controlled trial","volume":"11","author":"Arthuso","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.011_bib78","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.euo.2024.04.002","article-title":"Phase 1\/2 randomized clinical trial of in-clinic acupuncture prior to bacillus calmette-gu\u00e9rin in patients with high-risk non-muscle-invasive bladder cancer","volume":"7","author":"Psutka","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:41:29Z","timestamp":1783114889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0094014326000376"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.011","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-Centered Approaches to Non\u2013Muscle-Invasive Bladder Cancer Care","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}